Therapeutic Targeting of Metadherin Suppresses Colorectal and Lung Cancer Progression and Metastasis

Colorectal and lung cancers account for one-third of all cancerrelated deaths worldwide. Previous studies suggested that metadherin (MTDH) is involved in the development of colorectal and lung cancers. However, how MTDH regulates the pathogenesis of these cancers remains largely unknown. Using genetically modified mouse models of spontaneous colorectal and lung cancers, we found that MTDH promotes cancer progression by facilitating Wnt activation and by inducing cytotoxic T-cell exhaustion, respectively. Moreover, we developed locked nucleic acid-modified (LNA) MTDH antisense oligonucleotides (ASO) that effectively and specifically suppress MTDH expression in vitro and in vivo. Treatments with MTDH ASOs in mouse models significantly attenuated progression and metastasis of colorectal, lung, and breast cancers. Our study opens a new avenue for developing therapies against colorectal and lung cancers by targeting MTDH using LNA-modified ASO. Significance: This study provides new insights into the mechanism of MTDH in promoting colorectal and lung cancers, as well as genetic and pharmacologic evidence supporting the development of MTDH-targeting therapeutics.

Automated summary

The study found that MTDH promotes the progression of colorectal and lung cancers by facilitating Wnt activation and inducing T-cell exhaustion. Treatment with MTDH antisense oligonucleotides effectively suppresses MTDH expression and significantly attenuates the progression and metastasis of these cancers.